8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Nov 26, 2025·SEC
Nephros, Inc.(NEPH)Earnings, Financials & Key Ratios
NEPH•NASDAQ
$3.23
$35M mkt cap·29.4× P/E·Price updated May 7, 2026
AboutNephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Show more
- Revenue$19M+32.7%
- EBITDA$1M+799.3%
- Net Income$1M+1513.5%
- EPS (Diluted)0.11+1471.4%
- Gross Margin61.13%-0.8%
- EBITDA Margin6.84%+577.9%
- Operating Margin6.1%+14285.1%
- Net Margin6.35%+1116.2%
- ROE12.71%+1355.2%
- ROIC14.21%+19044.7%
- Debt/Equity0.10-36.6%
- Interest Coverage1146.00+1173.3%
NEPH Key Insights
Nephros, Inc. (NEPH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 17.0%
- ✓Efficient asset utilization: 1.4x turnover
✗Weaknesses
- ✗Weak momentum: RS Rating 13 (bottom 13%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NEPH Price & Volume
Nephros, Inc. (NEPH) stock price & volume — 10-year historical chart
Loading chart...
NEPH Growth Metrics
Nephros, Inc. (NEPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years25.46%
5 Years17.02%
3 Years23.5%
TTM23.25%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-3.12%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-10.07%
Return on Capital
10 Years-39.49%
5 Years-12.04%
3 Years-1.75%
Last Year11.17%
NEPH Peer Comparison
Nephros, Inc. (NEPH) competitors in Wound care and infection prevention — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CNMD | 1.17B | 38.09 | 25.22 | 5.16% | 4% | 5.4% | 0.81 | |
 NVCR | 1.92B | 16.83 | -13.80 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ANGO | 468.54M | 11.27 | -13.58 | -3.76% | -9.02% | -15.71% | ||
 NX | 916.46M | 20.07 | -3.70 | 43.81% | -13% | -30.23% | 1.18 | |
 FELE | 4.41B | 99.94 | 30.75 | 5.44% | 6.91% | 11.44% | 0.21 | |
 CWCO | 529.06M | 33.18 | -1.41% | 13.88% | 0% | 0.00 | ||
 DHR | 124.33B | 175.66 | 34.85 | 2.9% | 14.89% | 7.06% | 0.35 | |
 PEN | 12.77B | 324.62 | 71.82 | 17.5% | 11.76% | 12.32% | 0.15 |
Compare NEPH vs Peers
Nephros, Inc. (NEPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NEPH Income Statement
Nephros, Inc. (NEPH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 3.81M | 5.69M | 10.33M | 8.56M | 10.22M | 9.97M | 14.24M | 14.16M | 18.79M | 19.12M |
| Revenue Growth % | 64.18% | 49.3% | 81.71% | -17.16% | 19.34% | -2.37% | 42.74% | -0.53% | 32.67% | 23.25% |
| Cost of Goods Sold | 1.52M | 2.48M | 4.25M | 3.65M | 4.58M | 5.24M | 5.83M | 5.44M | 7.3M | 7.8M |
| COGS % of Revenue | 39.83% | 43.68% | 41.13% | 42.61% | 44.87% | 52.57% | 40.97% | 38.41% | 38.87% | - |
| Gross Profit | 2.29M▲ 0% | 3.2M▲ 39.7% | 6.08M▲ 89.9% | 4.91M▼ 19.2% | 5.63M▲ 14.7% | 4.73M▼ 16.0% | 8.4M▲ 77.7% | 8.72M▲ 3.8% | 11.48M▲ 31.7% | 11.32M▲ 0% |
| Gross Margin % | 60.17% | 56.32% | 58.87% | 57.39% | 55.13% | 47.43% | 59.03% | 61.59% | 61.13% | 59.21% |
| Gross Profit Growth % | 77.13% | 39.75% | 89.95% | -19.25% | 14.66% | -16.01% | 77.66% | 3.78% | 31.66% | - |
| Operating Expenses | 4.52M | 6.22M | 9.24M | 9.19M | 8.88M | 9.07M | 10M | 8.72M | 10.34M | 10.62M |
| OpEx % of Revenue | 118.61% | 109.35% | 89.4% | 107.32% | 86.96% | 90.89% | 70.22% | 61.55% | 55.03% | - |
| Selling, General & Admin | 3.3M | 4.52M | 6.12M | 6.47M | 7.2M | 7.59M | 8.91M | 7.68M | 9M | 9.27M |
| SG&A % of Revenue | 86.58% | 79.43% | 59.21% | 75.53% | 70.42% | 76.12% | 62.59% | 54.2% | 47.9% | - |
| Research & Development | 1M | 1.54M | 3.09M | 2.76M | 1.5M | 1.25M | 873K | 906K | 1.34M | 1.39M |
| R&D % of Revenue | 26.31% | 27.06% | 29.9% | 32.23% | 14.66% | 12.58% | 6.13% | 6.4% | 7.13% | - |
| Other Operating Expenses | 218K | -35K | 30K | -37K | 192K | 218K | 214K | 135K | 0 | -39K |
| Operating Income | -2.23M▲ 0% | -3.02M▼ 35.5% | -3.15M▼ 4.6% | -4.28M▼ 35.5% | -3.25M▲ 23.9% | -4.33M▼ 33.3% | -1.59M▲ 63.3% | 6K▲ 100.4% | 1.15M▲ 19000.0% | 677K▲ 0% |
| Operating Margin % | -58.44% | -53.03% | -30.53% | -49.94% | -31.83% | -43.46% | -11.19% | 0.04% | 6.1% | 3.54% |
| Operating Income Growth % | 22.41% | -35.49% | -4.61% | -35.5% | 23.93% | -33.3% | 63.25% | 100.38% | 19000% | - |
| EBITDA | -2.01M | -2.85M | -2.96M | -4.07M | -3M | -3.76M | -1.38M | 143K | 1.29M | 806K |
| EBITDA Margin % | -52.72% | -50.17% | -28.59% | -47.51% | -29.36% | -37.73% | -9.69% | 1.01% | 6.84% | 4.21% |
| EBITDA Growth % | 23.91% | -42.08% | -3.58% | -37.63% | 26.24% | -25.47% | 63.36% | 110.37% | 799.3% | -12.01% |
| D&A (Non-Cash Add-back) | 218K | 163K | 200K | 208K | 252K | 571K | 214K | 137K | 140K | 129K |
| EBIT | -2.3M | -3.25M | -3.21M | -4.42M | -2.74M | -4.26M | -1.57M | 90K | 1.15M | 588K |
| Net Interest Income | -298K | -168K | -195K | -99K | -31K | -6K | 62K | 93K | 138K | 125K |
| Interest Income | 4K | 4K | 0 | 11K | 10K | 14K | 64K | 94K | 139K | 158K |
| Interest Expense | 302K | 172K | 195K | 110K | 41K | 20K | 2K | 1K | 1K | 1K |
| Other Income/Expense | -372K | -402K | -249K | -251K | 468K | 58K | 18K | 83K | 60K | 111K |
| Pretax Income | -2.6M▲ 0% | -3.42M▼ 31.6% | -3.4M▲ 0.4% | -4.53M▼ 33.0% | -2.78M▲ 38.5% | -4.28M▼ 53.6% | -1.57M▲ 63.2% | 89K▲ 105.7% | 1.21M▲ 1255.1% | 788K▲ 0% |
| Pretax Margin % | -68.21% | -60.1% | -32.94% | -52.87% | -27.25% | -42.88% | -11.06% | 0.63% | 6.42% | 4.12% |
| Income Tax | -1.79M | -93K | -225K | 0 | 0 | 0 | 0 | 15K | 12K | 12K |
| Effective Tax Rate % | 68.86% | 2.72% | 6.61% | 0% | 0% | 0% | 0% | 16.85% | 1% | 1.52% |
| Net Income | -809K▲ 0% | -3.4M▼ 320.5% | -3.42M▼ 0.5% | -4.77M▼ 39.4% | -4.11M▲ 13.8% | -7.38M▼ 79.7% | -1.57M▲ 78.7% | 74K▲ 104.7% | 1.19M▲ 1513.5% | 776K▲ 0% |
| Net Margin % | -21.24% | -59.82% | -33.09% | -55.67% | -40.2% | -74% | -11.06% | 0.52% | 6.35% | 4.06% |
| Net Income Growth % | 73.32% | -320.52% | -0.53% | -39.36% | 13.83% | -79.74% | 78.66% | 104.7% | 1513.51% | -3.12% |
| Net Income (Continuing) | -809K | -3.33M | -3.18M | -4.53M | -2.78M | -4.28M | -1.57M | 74K | 1.19M | 776K |
| Discontinued Operations | 0 | 0 | 0 | 0 | -1.08M | -2.83M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 3M | 3.01M | 3.05M | 3.05M | 3.29M | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.14▲ 0% | -0.50▼ 257.1% | -0.42▲ 16.0% | -0.52▼ 23.8% | -0.41▲ 21.2% | -0.72▼ 75.6% | -0.15▲ 79.2% | 0.01▲ 104.7% | 0.11▲ 1471.4% | 0.07▲ 0% |
| EPS Growth % | 75% | -257.14% | 16% | -23.81% | 21.15% | -75.61% | 79.17% | 104.67% | - | -10.07% |
| EPS (Basic) | -0.14 | -0.50 | -0.42 | -0.52 | -0.41 | -0.72 | -0.15 | 0.01 | 0.11 | - |
| Diluted Shares Outstanding | 5.88M | 6.85M | 7.54M | 9.08M | 10.02M | 10.3M | 10.39M | 10.6M | 10.97M | 10.99M |
| Basic Shares Outstanding | 5.88M | 6.85M | 7.54M | 9.08M | 10.02M | 10.3M | 10.39M | 10.53M | 10.61M | 10.65M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NEPH Balance Sheet
Nephros, Inc. (NEPH) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.81M | 8.17M | 8.3M | 15.15M | 13.63M | 8.26M | 8.4M | 8.3M | 11.22M | 11.5M |
| Cash & Short-Term Investments | 2.21M | 4.58M | 4.17M | 8.25M | 6.97M | 3.63M | 4.31M | 3.76M | 5.4M | 4.02M |
| Cash Only | 2.19M | 4.58M | 4.17M | 8.25M | 6.97M | 3.63M | 4.31M | 3.76M | 5.4M | 4.02M |
| Short-Term Investments | 20K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 836K | 1.45M | 1.27M | 1.36M | 1.64M | 1.29M | 1.5M | 1.78M | 2.41M | 3.52M |
| Days Sales Outstanding | 80.11 | 93.19 | 44.86 | 58.15 | 58.62 | 47.06 | 38.35 | 45.9 | 46.9 | 50.75 |
| Inventory | 674K | 1.86M | 2.56M | 5.3M | 4.46M | 3.15M | 2.47M | 2.62M | 3.23M | 3.62M |
| Days Inventory Outstanding | 162.17 | 273.9 | 220.03 | 530.69 | 355.29 | 219.46 | 154.56 | 175.49 | 161.51 | 138.35 |
| Other Current Assets | 26K | 231K | 0 | 0 | 351K | 0 | 132K | 142K | 177K | 338K |
| Total Non-Current Assets | 1.17M | 2.38M | 3.33M | 3.36M | 4.02M | 2.74M | 3.46M | 2.91M | 2.42M | 2.3M |
| Property, Plant & Equipment | 52K | 91K | 1.19M | 1.33M | 686K | 1.1M | 1.96M | 1.54M | 1.13M | 1.02M |
| Fixed Asset Turnover | 73.25x | 62.49x | 8.71x | 6.43x | 14.89x | 9.07x | 7.27x | 9.21x | 16.67x | 16.23x |
| Goodwill | 0 | 748K | 759K | 759K | 759K | 759K | 759K | 759K | 759K | 759K |
| Intangible Assets | 1.07M | 1.53M | 1.35M | 1.18M | 1M | 825K | 652K | 565K | 318K | 310K |
| Long-Term Investments | 39K | 0 | 0 | 36K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 11K | 18K | 32K | 53K | 1.57M | 54K | 86K | 50K | 214K | 884K |
| Total Assets | 4.98M▲ 0% | 10.56M▲ 111.9% | 11.63M▲ 10.1% | 18.51M▲ 59.2% | 17.65M▼ 4.6% | 11M▼ 37.7% | 11.86M▲ 7.8% | 11.21M▼ 5.5% | 13.64M▲ 21.7% | 13.79M▲ 0% |
| Asset Turnover | 0.76x | 0.54x | 0.89x | 0.46x | 0.58x | 0.91x | 1.20x | 1.26x | 1.38x | 1.45x |
| Asset Growth % | 86.07% | 111.88% | 10.14% | 59.17% | -4.65% | -37.68% | 7.84% | -5.49% | 21.69% | 76.65% |
| Total Current Liabilities | 1.87M | 2.65M | 2.43M | 1.32M | 2.39M | 1.41M | 2.11M | 1.56M | 2.77M | 2.53M |
| Accounts Payable | 872K | 836K | 959K | 423K | 1.33M | 740K | 873K | 649K | 914K | 1.46M |
| Days Payables Outstanding | 209.81 | 122.84 | 82.36 | 42.32 | 106.22 | 51.51 | 54.63 | 43.55 | 45.67 | 46.15 |
| Short-Term Debt | 711K | 1.19M | 771K | 229K | 248K | 71K | 0 | 0 | 391K | 402K |
| Deferred Revenue (Current) | 70K | 396K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 590K | 300K | 0 | 51K | 0 | 0 | 0 | 1.37M | 2.13M |
| Current Ratio | 2.04x | 3.08x | 3.42x | 11.44x | 5.70x | 5.85x | 3.98x | 5.31x | 4.06x | 4.06x |
| Quick Ratio | 1.68x | 2.38x | 2.36x | 7.43x | 3.84x | 3.62x | 2.81x | 3.64x | 2.89x | 2.89x |
| Cash Conversion Cycle | 32.47 | 244.25 | 182.53 | 546.52 | 307.69 | 215.01 | 138.28 | 177.84 | 162.73 | 142.95 |
| Total Non-Current Liabilities | 1.16M | 1.11M | 1.51M | 1.61M | 511K | 706K | 1.39M | 1.06M | 672K | 566K |
| Long-Term Debt | 954K | 843K | 623K | 853K | 99K | 1K | 0 | 0 | 0 | 566K |
| Capital Lease Obligations | 0 | 0 | 889K | 759K | 340K | 705K | 1.39M | 1.06M | 672K | 2.32M |
| Deferred Tax Liabilities | -208K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 263K | 0 | 0 | 72K | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 3.03M | 3.76M | 3.94M | 2.94M | 2.9M | 2.12M | 3.5M | 2.63M | 3.44M | 3.09M |
| Total Debt | 1.67M | 2.03M | 2.54M | 2.17M | 1M | 1.09M | 1.84M | 1.41M | 1.06M | 968K |
| Net Debt | -529K | -2.55M | -1.62M | -6.08M | -5.97M | -2.54M | -2.47M | -2.35M | -4.34M | -3.05M |
| Debt / Equity | 0.85x | 0.30x | 0.33x | 0.14x | 0.07x | 0.12x | 0.22x | 0.16x | 0.10x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - | - | 9.87x | 0.83x | 1.20x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -16.43x | -3.37x | -3.37x |
| Interest Coverage | -7.60x | -18.87x | -16.46x | -40.15x | -66.90x | -212.85x | -786.50x | 90.00x | 1146.00x | 588.00x |
| Total Equity | 1.95M▲ 0% | 6.8M▲ 248.6% | 7.69M▲ 13.1% | 15.57M▲ 102.5% | 14.75M▼ 5.3% | 8.88M▼ 39.8% | 8.36M▼ 5.9% | 8.59M▲ 2.7% | 10.2M▲ 18.8% | 10.7M▲ 0% |
| Equity Growth % | 192.35% | 248.62% | 13.11% | 102.54% | -5.29% | -39.79% | -5.89% | 2.72% | 18.84% | 77.53% |
| Book Value per Share | 0.33 | 0.99 | 1.02 | 1.72 | 1.47 | 0.86 | 0.80 | 0.81 | 0.93 | 0.97 |
| Total Shareholders' Equity | 1.95M | 3.8M | 4.67M | 12.52M | 11.7M | 5.59M | 8.36M | 8.59M | 10.2M | 10.7M |
| Common Stock | 55K | 64K | 8K | 10K | 10K | 10K | 10K | 11K | 11K | 11K |
| Retained Earnings | -121.11M | -124.15M | -127.33M | -131.86M | -135.72M | -142.83M | -144.41M | -144.33M | -143.14M | -143M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 77K | 71K | 65K | 74K | 64K | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 3M | 3.01M | 3.05M | 3.05M | 3.29M | 0 | 0 | 0 | 0 |
NEPH Cash Flow Statement
Nephros, Inc. (NEPH) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -77K | -3.66M | -2.28M | -6.9M | -1.42M | -3.23M | 827K | -492K | 1.65M | 1.65M |
| Operating CF Margin % | -2.02% | -64.39% | -22.02% | -80.63% | -13.87% | -32.42% | 5.81% | -3.47% | 8.76% | - |
| Operating CF Growth % | 96.35% | -4655.84% | 37.85% | -203.3% | 79.47% | -128.23% | 125.57% | -159.49% | 434.35% | -287.01% |
| Net Income | -809K | -3.33M | -3.18M | -4.53M | -3.87M | -4.55M | -1.57M | 74K | 1.19M | 776K |
| Depreciation & Amortization | 218K | 163K | 200K | 208K | 252K | 351K | 214K | 137K | 139K | 126K |
| Stock-Based Compensation | 772K | 985K | 1.33M | 779K | 1.26M | 952K | 1.05M | 153K | 296K | 210K |
| Deferred Taxes | 0 | 322K | 56K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 135K | 45K | -105K | 129K | 56K | -213K | 648K | 698K | 429K | -1.46M |
| Working Capital Changes | -393K | -1.85M | -580K | -3.49M | 883K | 229K | 488K | -1.55M | -413K | -2K |
| Change in Receivables | -416K | -484K | 392K | -333K | -278K | 357K | -221K | -285K | -633K | -844K |
| Change in Inventory | -195K | -1.08M | -735K | -2.76M | 296K | 915K | 387K | -407K | -685K | -1.74M |
| Change in Payables | 268K | -130K | 119K | -538K | 908K | -593K | 133K | -220K | 259K | 614K |
| Cash from Investing | 0 | -991K | -151K | -239K | -85K | -137K | -75K | -50K | 0 | 0 |
| Capital Expenditures | 0 | 0 | -14K | -239K | -36K | -137K | -75K | -55K | 0 | 0 |
| CapEx % of Revenue | - | - | 0.14% | 2.79% | 0.35% | 1.37% | 0.53% | 0.39% | - | - |
| Acquisitions | 0 | -991K | -137K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -49K | 0 | 0 | 5K | 0 | 0 |
| Cash from Financing | 1.99M | 7.05M | 2.02M | 11.22M | 237K | 34K | -79K | -5K | -5K | 285K |
| Debt Issued (Net) | 711K | 131K | -633K | -321K | -264K | -286K | -79K | -5K | -5K | -4K |
| Equity Issued (Net) | 1.18M | 3.78M | 1.99M | 11.45M | 501K | 163K | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 100K | 3.14M | 658K | 85K | 0 | 157K | 0 | 0 | 0 | 289K |
| Net Change in Cash | 1.92M▲ 0% | 2.39M▲ 24.4% | -415K▼ 117.4% | 4.08M▲ 1083.9% | -1.28M▼ 131.3% | -3.34M▼ 161.7% | 673K▲ 120.2% | -547K▼ 181.3% | 1.64M▲ 399.8% | -63K▲ 0% |
| Free Cash Flow | -77K▲ 0% | -3.66M▼ 4655.8% | -2.29M▲ 37.5% | -7.14M▼ 211.9% | -1.45M▲ 79.7% | -3.37M▼ 132.0% | 752K▲ 122.3% | -547K▼ 172.7% | 1.65M▲ 400.7% | -348K▲ 0% |
| FCF Margin % | -2.02% | -64.39% | -22.16% | -83.42% | -14.22% | -33.79% | 5.28% | -3.86% | 8.76% | -1.82% |
| FCF Growth % | 96.43% | -4655.84% | 37.47% | -211.88% | 79.66% | -132% | 122.31% | -172.74% | 400.73% | -177.85% |
| FCF per Share | -0.01 | -0.53 | -0.30 | -0.79 | -0.15 | -0.33 | 0.07 | -0.05 | 0.15 | 0.15 |
| FCF Conversion (FCF/Net Income) | 0.10x | 1.08x | 0.67x | 1.45x | 0.35x | 0.44x | -0.53x | -6.65x | 1.38x | -0.45x |
| Interest Paid | 148K | 150K | 139K | 93K | 41K | 0 | 0 | 0 | 0 | 1K |
| Taxes Paid | 7K | 4K | 5K | 22K | 79K | 0 | 0 | 0 | 0 | 0 |
NEPH Key Ratios
Nephros, Inc. (NEPH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -61.83% | -77.78% | -47.21% | -40.98% | -27.09% | -62.48% | -18.27% | 0.87% | 12.71% | 7.66% |
| Return on Invested Capital (ROIC) | -125.95% | -79.83% | -45.88% | -41.2% | -26.7% | -43.02% | -19.54% | 0.07% | 14.21% | 14.21% |
| Gross Margin | 60.17% | 56.32% | 58.87% | 57.39% | 55.13% | 47.43% | 59.03% | 61.59% | 61.13% | 59.21% |
| Net Margin | -21.24% | -59.82% | -33.09% | -55.67% | -40.2% | -74% | -11.06% | 0.52% | 6.35% | 4.06% |
| Debt / Equity | 0.85x | 0.30x | 0.33x | 0.14x | 0.07x | 0.12x | 0.22x | 0.16x | 0.10x | 0.10x |
| Interest Coverage | -7.60x | -18.87x | -16.46x | -40.15x | -66.90x | -212.85x | -786.50x | 90.00x | 1146.00x | 588.00x |
| FCF Conversion | 0.10x | 1.08x | 0.67x | 1.45x | 0.35x | 0.44x | -0.53x | -6.65x | 1.38x | -0.45x |
| Revenue Growth | 64.18% | 49.3% | 81.71% | -17.16% | 19.34% | -2.37% | 42.74% | -0.53% | 32.67% | 23.25% |
NEPH SEC Filings & Documents
Nephros, Inc. (NEPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
NEPH Frequently Asked Questions
Nephros, Inc. (NEPH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nephros, Inc. (NEPH) reported $19.1M in revenue for fiscal year 2025.
Nephros, Inc. (NEPH) grew revenue by 32.7% over the past year. This is strong growth.
Yes, Nephros, Inc. (NEPH) is profitable, generating $0.8M in net income for fiscal year 2025 (6.4% net margin).
Dividend & Returns
Nephros, Inc. (NEPH) has a return on equity (ROE) of 12.7%. This is reasonable for most industries.
Nephros, Inc. (NEPH) had negative free cash flow of $0.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More NEPH
Nephros, Inc. (NEPH) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates